Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Spatially varying effects of predictors for the survival prediction of nonmetastatic colorectal Cancer

Authors: Yu Tian, Jun Li, Tianshu Zhou, Danyang Tong, Shengqiang Chi, Xiangxing Kong, Kefeng Ding, Jingsong Li

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

An increasing number of studies have identified spatial differences in colorectal cancer survival. However, little is known about the spatially varying effects of predictors in survival prediction modeling studies of colorectal cancer that have focused on estimating the absolute survival risk for patients from a wide range of populations. This study aimed to demonstrate the spatially varying effects of predictors of survival for nonmetastatic colorectal cancer patients.

Methods

Patients diagnosed with nonmetastatic colorectal cancer from 2004 to 2013 who were followed up through the end of 2013 were extracted from the Surveillance Epidemiology End Results registry (Patients: 128061). The log-rank test and the restricted mean survival time were used to evaluate survival outcome differences among spatial clusters corresponding to a widely used clinical predictor: stage determined by AJCC 7th edition staging system. The heterogeneity test, which is used in meta-analyses, revealed the spatially varying effects of single predictors. Then, considering the above predictors in a standard survival prediction model based on spatially clustered data, the spatially varying coefficients of these models revealed that some covariate effects may not be constant across the geographic regions of the study. Then, two types of survival prediction models (a statistical model and a machine learning model) were built; these models considered the predictors and enabled survival prediction for patients from a wide range of geographic regions.

Results

Based on univariate and multivariate analysis, some prognostic factors, such as “TNM stage”, “tumor size” and “age at diagnosis,” have significant spatially varying effects among different regions. When considering these spatially varying effects, machine learning models have fewer assumption constraints (such as proportional hazard assumptions) and better predictive performance compared with statistical models. Upon comparing the concordance indexes of these two models, the machine learning model was found to be more accurate (0.898[0.895,0.902]) than the statistical model (0.732 [0.726, 0.738]).

Conclusions

Based on this study, it’s recommended that the spatially varying effect of predictors should be considered when building survival prediction models involving large-scale and multicenter research data. Machine learning models that are not limited by the requirement of a statistical hypothesis are promising alternative models.
Appendix
Available only for authorised users
Literature
3.
go back to reference Tervonen HE, Morrell S, Aranda S, Roder D, You H, Niyonsenga T, et al. The impact of geographic unit of analysis on socioeconomic inequalities in cancer survival and distant summary stage–a population-based study. Aust N Z J Public Health. 2017;41:130–6.CrossRefPubMed Tervonen HE, Morrell S, Aranda S, Roder D, You H, Niyonsenga T, et al. The impact of geographic unit of analysis on socioeconomic inequalities in cancer survival and distant summary stage–a population-based study. Aust N Z J Public Health. 2017;41:130–6.CrossRefPubMed
5.
go back to reference Sleightholm R, Foster JM, Smith L, Ceelen W, Deraco M, Yildirim Y, et al. The American Society of Peritoneal Surface Malignancies multi-institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: an introduction of the peritoneal surface disease severity score. J Surg Oncol. 2016;114:779–84. https://doi.org/10.1002/jso.24406.CrossRefPubMed Sleightholm R, Foster JM, Smith L, Ceelen W, Deraco M, Yildirim Y, et al. The American Society of Peritoneal Surface Malignancies multi-institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: an introduction of the peritoneal surface disease severity score. J Surg Oncol. 2016;114:779–84. https://​doi.​org/​10.​1002/​jso.​24406.CrossRefPubMed
13.
go back to reference Dalton ARH. Incomplete diagnostic follow-up after a positive colorectal cancer screening test: a systematic review. J Public Health. 2017;40(1):e46–58. Dalton ARH. Incomplete diagnostic follow-up after a positive colorectal cancer screening test: a systematic review. J Public Health. 2017;40(1):e46–58.
27.
go back to reference Hsieh CF, Cramb SM, Mcgree JM, Dunn NAM, Baade PD, Mengersen KL. Does geographic location impact the survival differential between screen- and interval-detected breast cancers? Stoch Env Res Risk A. 2016;30:155–65.CrossRef Hsieh CF, Cramb SM, Mcgree JM, Dunn NAM, Baade PD, Mengersen KL. Does geographic location impact the survival differential between screen- and interval-detected breast cancers? Stoch Env Res Risk A. 2016;30:155–65.CrossRef
33.
go back to reference Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat. 1982;10:1100–20.CrossRef Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat. 1982;10:1100–20.CrossRef
Metadata
Title
Spatially varying effects of predictors for the survival prediction of nonmetastatic colorectal Cancer
Authors
Yu Tian
Jun Li
Tianshu Zhou
Danyang Tong
Shengqiang Chi
Xiangxing Kong
Kefeng Ding
Jingsong Li
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4985-2

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine